Background COVID-19 is associated with a prothrombotic state leading to adverse clinical
outcomes. Whether therapeutic anticoagulation improves outcomes in patients hospitalised …

Coronavirus disease 2019 (COVID‐19) is associated with a hypercoagulable state. It has
been hypothesized that higher‐dose anticoagulation, including therapeutic‐dose and …

Background COVID-19 infection is associated with D-dimer elevations, high rates of
thrombus formation, and poor clinical outcomes. We sought to determine if empiric …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Background Mortality in coronavirus disease of 2019 (COVID-19) is associated with
increases in prothrombotic parameters, particularly D-dimer levels. Anticoagulation has …

Emerging evidence shows that severe coronavirus disease 2019 (COVID‐19) can be
complicated with coagulopathy, namely disseminated intravascular coagulation, which has …

Objective: Examine the possible beneficial effects of early, D-dimer driven anticoagulation in
preventing thrombotic complications and improving the overall outcomes of COVID-19 …

Background Thrombosis and inflammation may contribute to the risk of death and
complications among patients with coronavirus disease 2019 (Covid-19). We hypothesized …

Background Coronavirus disease 2019 (COVID‐19) is a respiratory disease associated with
thrombotic outcomes with coagulation and endothelial disorders. Based on that, several …

Background Thromboprophylaxis of COVID-19 patients is a highly debated issue. We aimed
to compare the occurrence of thrombotic/ischemic events in COVID-19 patients with acute …